Wall Street analysts tipped 2024 as the year that medtech dealmaking would return after a two-year slowdown when companies were forced to navigate a tough economic environment, complicated by the COVID-19 pandemic still pressuring businesses. There have been few big-name, billion-dollar deals so far this year, though a steady amount of M&A news has come out of the sector.
Read the full article: Boston Scientific’s $3.7B Axonics Buy Tops List of Medtech M&A in 2024 //
Source: https://www.medtechdive.com/news/medtech-deals-2024-boston-scientific-axonics/711574